MARKETS / BALCAO / USAQ
BALCAO · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

QHSLab, Inc. USAQ

16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.7M
▲ 26.3% vs FY2024
EPS · FY25
$0.02
Dividend / sh · FY25
Payout · FY25
ROE · FY25
89.9%
Net margin · FY25
17.0%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.7M
Revenue, FY2025 · full 16-year series below
Revenue Net income
0.00080.00160.00240.00320.00.0201020132016201920222025
0.00080.00160.00240.00320.00.02016201920222025

17 cents of every revenue dollar became profit this year.

Per share
USD 0.02
Diluted EPS, FY2025
EPS
0.40.81.20.02201020132016201920222025
0.40.81.20.022016201920222025

The company pays no cash dividend.

Profitability
89.9%
Return on equity, FY2025
ROE
25507510089.9%201020132016201920222025
25507510089.9%2016201920222025
Operating margin4.9%
Net margin17.0%
Return on assets23.0%

Each USD of equity produced 90 cents of profit this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+84.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+29.4%
+84.9%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.02B
Shares outstanding, FY2025
0.010.02201020132016201920222025
0.000.022016201920222025
Change, 5 years+129.1%
Change, 10 years

The share count grew 129% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.2M
total assets, end of FY2025
Total assetsUSD 2.2M
EquityUSD 1.6M
CashUSD 636,157.00
Gross debtUSD 90,704.00
Net debtUSD -545,453.00
Current ratio1.96×

The company holds more cash than debt.

History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
·
EBITDA $B
0.0
0.0
−0.0
−0.0
−0.0
·
·
·
·
·
·
·
·
·
·
·
Income tax $B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
0.02
−0.03
−0.05
−0.11
−0.10
−0.05
−0.03
0.00
0.00
0.00
−0.23
−0.04
−0.06
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
89.9
·
·
−221.3
−714.0
·
·
·
·
·
·
·
·
·
·
·
Shares out B
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.00
0.00
0.00
0.01
·
·
·
·
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
45 of 45
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed